DOCSLIB.ORG

Microbiology & Infectious Diseases

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

MICROBIOLOGY & INFECTIOUS DISEASES Vol. 2.1 August 2021 emjreviews.com ECCMID 2021 EDITOR’S PICK Gross, Histopathological, and Ultrastructural Features in Patients with COVID-19: A Literature Review INTERVIEWS Nicola Rose and Sarah Caddy, two internationally renowned microbiology and infectious diseases experts, provide insights into the COVID-19 vaccination programmes and discuss their research interests and recent publications. Contents + EDITORIAL BOARD 4 + WELCOME 7 + FOREWORD 9 + CONGRESS REVIEW Review of the 31st European Congress of Clinical Microbiology and 13 Infectious Diseases (ECCMID) 2021 + ABSTRACT REVIEWS Is the Delayed Antibiotic Prescribing Strategy Effective for Reducing 24 the Use of Antibiotics? Llor et al. Antibiotic Stewardship Attitudes and Beliefs Among Front-line Staff 26 Nurses: Impact of Virtual Education in the COVID-19 Era Polisetty et al. Be Conscious of Cryptococcus neoformans: Cryptococcal 28 Meningoencephalitis and Cryptococcaemia with Unfavourable Outcome in a Patient with Myasthenia Gravis Ieronymaki et al. A Single-Centre Retrospective Study on the Impact of Reducing 29 Surgical Prophylaxis from 48 Hours to 24 Hours in Cardiovascular Surgery Lim et al. Evaluation of Vaccination Effectiveness Against SARS-CoV-2 in 31 Healthcare Professionals Tsalidou et al. Direct Linkage Between the Prevalence of Known Common Extra- 33 intestinal Pathogenic Escherichia coli Sequence Types in UK Sewage to Those Causing E. coli Urinary Tract Infections and Sepsis Mathias et al. 2 MICROBIOL & INFECT DIS • August 2021 EMJ “Summaries of stand-out poster presentations are included in this issue, covering topics such as the impact of inflammatory bowel disease on the risk of periprosthetic joint infection, the use of plasma-activated water to combat multidrug-resistant bacteria, and much more.” Spencer Gore, CEO Aspergillus Sensitisation in Patients with Severe Asthma 35 Kozlova et al. Do Infections Start in the Gut? Patients with Inflammatory Bowel 37 Disease Have a Higher Risk of Periprosthetic Joint Infection after Surgery Chisari et al. Plasma-Activated Water as a New Weapon Against Multidrug-Resistant 38 Bacteria Abdo et al. + INTERVIEWS Nicola Rose 40 Sarah Caddy 44 + ARTICLES Editor’s Pick: Gross, Histopathological, and Ultrastructural Features in 46 Patients with COVID-19: A Literature Review Hussain et al. The PPE Pandemic: Sex-Related Discrepancies of N95 Mask Fit 57 Christopher et al. Impact of COVID-19 Pandemic on Trauma and Orthopaedic Service in 65 the Republic of Ireland Elbardesy Implications and Aspects of Lyme Neuroborreliosis 72 Riggle and Brissette Disseminated Phaeohyphomycotic Lymphadenitis with 80 Cladophialophora Species Moin et al. Cutaneous Mucormycosis of the Interscapular Region in an 85 Immunocompetent Patient Doshi et al. Creative Commons Attribution-Non Commercial 4.0 August 2021 • MICROBIOL & INFECT DIS 3 Editorial Board Editor-in-Chief Prof Rajeshwar Reddy Kasarla Universal College of Medical Sciences, Nepal Editorial Board Prof Zamberi Bin Sekawi Universiti Putra Malaysia, Malaysia Dr Ali Elbeddini University of Ottawa, Canada Dr Emilio Bouza Hospital Gregorio Marañón, Spain Dr Mohammed Nazish Farwaniya Hospital, Kuwait Dr Muge Cevik University of St Andrews, UK Dr Hisham Elkhayat Theodor Bilharz Research Institute, Egypt Dr Oliver Grundmann University of Florida, USA Dr Smita Shevade Millennium Path Lab, India Dr Rahul Garg Banaras Hindu University, India Dr Poonam Gupta SUASTH Healthcare, India Dr Sanjay Bhattacharya Fakhruddin Medical College, India Dr Manisha Gupta Super Speciality Cancer Institute and Hospital, India VIEW IN FULL 4 MICROBIOL & INFECT DIS • August 2021 EMJ Aims and Scope We are always keen to hear from healthcare professionals wishing to discuss potential submissions, please email: EMJ is an online only, peer-reviewed, open access general [email protected] journal, targeted towards readers in the medical sciences. We aim to make all our articles accessible to readers from To submit a paper, use our online submission site: any medical discipline. www.editorialmanager.com/e-m-j EMJ allows healthcare professionals to stay abreast of Submission details can be found through our website: key advances and opinions across Europe. www.emjreviews.com/contributors/authors EMJ aims to support healthcare professionals in continuously developing their knowledge, effectiveness, Reprints and productivity. The editorial policy is designed to All articles included in EMJ are available as reprints encourage discussion among this peer group. (minimum order 1,000). Please contact Editor-in-Chief EMJ is published quarterly and comprises review articles, [email protected] if you would like to order reprints. Prof Rajeshwar Reddy Kasarla Universal College of Medical Sciences, Nepal case reports, practice guides, theoretical discussions, and original research. Distribution and Readership EMJ also publishes 16 therapeutic area journals, which EMJ is distributed through controlled circulation to Editorial Board provide concise coverage of salient developments at healthcare professionals in the relevant fields the leading European congresses. These are published across Europe. Prof Zamberi Bin Sekawi Universiti Putra Malaysia, Malaysia annually, approximately 6 weeks after the relevant congress. Further details can be found on our website: Indexing and Availability Dr Ali Elbeddini University of Ottawa, Canada www.emjreviews.com EMJ is indexed on DOAJ, the Royal Society of Medicine, Dr Emilio Bouza Hospital Gregorio Marañón, Spain and Google Scholar®; selected articles are indexed in Editorial Expertise PubMed Central®. Dr Mohammed Nazish Farwaniya Hospital, Kuwait EMJ is supported by various levels of expertise: EMJ is available through the websites of our leading Dr Muge Cevik University of St Andrews, UK • Guidance from an Editorial Board consisting of leading partners and collaborating societies. authorities from a wide variety of disciplines. EMJ journals are all available via our website: Dr Hisham Elkhayat Theodor Bilharz Research Institute, Egypt • Invited contributors are recognised authorities from www.emjreviews.com their respective fields. Dr Oliver Grundmann University of Florida, USA • Peer review, which is conducted by EMJ’s Peer Review Open Access Dr Smita Shevade Millennium Path Lab, India Panel as well as other experts appointed due to their knowledge of a specific topic. This is an open-access journal in accordance with the Creative Commons Attribution-Non Commercial 4.0 Dr Rahul Garg Banaras Hindu University, India • An experienced team of editors and technical editors. (CC BY-NC 4.0) license. Dr Poonam Gupta SUASTH Healthcare, India Peer Review Congress Notice Dr Sanjay Bhattacharya Fakhruddin Medical College, India On submission, all articles are assessed by the editorial Staff members attend medical congresses as reporters team to determine their suitability for the journal and when required. Dr Manisha Gupta Super Speciality Cancer Institute and Hospital, India appropriateness for peer review. Editorial staff, following consultation with either a This Publication member of the Editorial Board or the author(s) if EMJ Microbiology and Infectious Diseases is published necessary, identify three appropriate reviewers, who are once selected based on their specialist knowledge in the a year. For subscription details please visit: relevant area. www.emjreviews.com All peer review is double blind. All information obtained by European Medical Journal Following review, papers are either accepted without and each of the contributions from various sources is as modification, returned to the author(s) to incorporate current and accurate as possible. However, due to human required changes, or rejected. or mechanical errors, European Medical Journal and the contributors cannot guarantee the accuracy, adequacy, Editorial staff have final discretion over any or completeness of any information, and cannot be held proposed amendments. responsible for any errors or omissions. European Medical Journal is completely independent of the review event Submissions (ECCMID 2021) and the use of the organisations does not constitute endorsement or media partnership We welcome contributions from professionals, in any form whatsoever. consultants, academics, and industry leaders on relevant and topical subjects. Front cover and contents photograph: Vienna, Austria, home of ECCMID 2021. © jakobradlgruber / 123rf.com We seek papers with the most current, interesting, and relevant information in each therapeutic area and accept original research, review articles, case reports, and features. Creative Commons Attribution-Non Commercial 4.0 August 2021 • MICROBIOL & INFECT DIS 5 EMJ Microbiology & Infectious Diseases 2.1 Chairman of Advisory Board Resourcer Prof Jonathan Sackier Nafia Kauser Chief Executive Officer Head of Operations Spencer Gore Keith Moule Chief Commercial Officer Operations Manager Daniel Healy Nikki Curtis Managing Director Operations Assistants Dan Scott Satkartar Chaggar, Emma Knight, April McCaffrey Executive Assistant Samantha Knights Editor Evgenia Koutsouki Head of Marketing Marc Koskela Editorial Managers Katherine Colvin, Anaya Malik Performance Manager Darren Brace Copy Editor Jaki Smith Senior Project Managers Kelly Byrne, Hayley Cooper, Nabihah Durrani, Editorial Assistants Millie McGowan, Max Roy Evan Kimber, Natasha Meunier-McVey, Janet Nzisa, Heeral Patel, Robin Stannard, Theo Wolf Client Services Manager Caleb Wright Editorial Administrator
Recommended publications
  • Isbn 978-625-409-353-1

    Isbn 978-625-409-353-1

    ISBN 978-625-409-353-1 INTERNATIONAL CONGRESS ON BIOLOGICAL AND HEALTH SCIENCES PROCEEDİNGS BOOK This work is subject to copyright and all rights reserved, whether the whole or part of the material is concerned. The right to publish this book belongs to International Congress on Biological and Health Sciences-2021. No part of this publication may be translated, reproduced, stored in a computerized system, or transmitted in any form or by any means, including, but not limited to electronic, mechanical, photocopying, recording without written permission from the publisher. This Proceedings Book has been published as an electronic publication (e-book). The publisher is not responsible for possible damages, which may be a result of content derived from this electronic publication All authors are responsible for the contents of their abstracts. https://www.biohealthcongress.com/ ([email protected]) Editor Ulaş ACARÖZ Published: 28/03/2021 ISBN: Editor's Note The first ‘International Congress on Biological and Health Sciences’ was organized online and free of charge. We are very happy and proud that various health science-related fields attended the congress. By this event, the distinguished and respected scientists came together to exchange ideas, develop and implement new researches and joint projects. There were 15 invited speakers from 10 different countries and also approximately 400 submissions were accepted from more than 20 countries. We would like to thank all participants and supporters. Hope to see you at our next congress.
  • Tonsillopharyngitis - Acute (1 of 10)

    Tonsillopharyngitis - Acute (1 of 10)

    Tonsillopharyngitis - Acute (1 of 10) 1 Patient presents w/ sore throat 2 EVALUATION Yes EXPERT Are there signs of REFERRAL complication? No 3 4 EVALUATION Is Group A Beta-hemolytic Yes DIAGNOSIS Streptococcus (GABHS) • Rapid antigen detection test infection suspected? (RADT) • roat culture No TREATMENT EVALUATION No A Supportive management Is GABHS confi rmed? B Pharmacological therapy (Non-GABHS) Yes 5 TREATMENT A EVALUATE RESPONSEMIMS Supportive management TO THERAPY C Pharmacological therapy • Antibiotics Poor/No Good D Surgery, if recurrent or complicated response response REASSESS PATIENT COMPLETE THERAPY & REVIEW THE DIAGNOSIS© Not all products are available or approved for above use in all countries. Specifi c prescribing information may be found in the latest MIMS. B269 © MIMS Pediatrics 2020 Tonsillopharyngitis - Acute (2 of 10) 1 ACUTE TONSILLOPHARYNGITIS • Infl ammation of the tonsils & pharynx • Etiologies include bacterial (group A β-hemolytic streptococcus, Haemophilus infl uenzae, Fusobacterium sp, etc) & viral (infl uenza, adenovirus, coronavirus, rhinovirus, etc) pathogens • Sore throat is the most common presenting symptom in older children TONSILLOPHARYNGITIS 2 EVALUATION FOR COMPLICATIONS • Patients w/ sore throat may have deep neck infections including epiglottitis, peritonsillar or retropharyngeal abscess • Examine for signs of upper airway obstruction Signs & Symptoms of Sore roat w/ Complications • Trismus • Inability to swallow liquids • Increased salivation or drooling • Peritonsillar edema • Deviation of uvula
  • Examining the Antimicrobial Activity of Cefepime-Taniborbactam

    Examining the Antimicrobial Activity of Cefepime-Taniborbactam

    Examining the antimicrobial activity of cefepime-taniborbactam (formerly cefepime/VNRX-5133) against Burkholderia species isolated from cystic fibrosis patients in the United States Elise T. Zeiser1, Scott A. Becka1, John J. LiPuma2, David A. Six 3, Greg Moeck 3, and Krisztina M. Papp-Wallace1,4 1Veterans Affairs Northeast Ohio Healthcare System, Cleveland, OH; 2University of Michigan, Ann Arbor, MI; 3Venatorx 4 Pharmaceuticals, Inc., Malvern, PA; and Case Western Reserve University, Cleveland, OH Correspondence to: [email protected] Abstract Results Background: Burkholderia cepacia complex (Bcc), a group of >20 related species, and B. gladioli are 60 opportunistic human pathogens that cause chronic infections in people with cystic fibrosis (CF) or cefepime compromised immune systems. Ceftazidime and trimethoprim-sulfamethoxazole are first-line agents used to treat infections due to Burkholderia spp. However, these species have developed resistance to cefepime-taniborbactam many antibiotics, including first-line therapies. β-lactam resistance in Burkholderia species is largely 40 mediated by PenA-like chromosomal class A β-lactamases. A novel investigational β-lactam/β-lactamase inhibitor combination, cefepime-taniborbactam (formerly cefepime/VNRX-5133) demonstrates potent antimicrobial activity against gram-negative bacteria producing class A, B, C, and D β-lactamases. The activity of cefepime-taniborbactam was investigated against Bcc and B. gladioli; moreover, the biochemical activity of taniborbactam against the PenA1 carbapenemase was evaluated. 20 Methods: CLSI-based agar dilution antimicrobial susceptibility testing using cefepime and cefepime combined with taniborbactam at 4 mg/L was conducted against a curated panel of 150 Burkholderia species obtained from the Burkholderia cepacia Research Laboratory and Repository. Isolates were Number isolates of recovered from respiratory specimens from 150 different individuals with CF receiving care in 68 cities 0 throughout 36 states within the United States.
  • Table S4. Phylogenetic Distribution of Bacterial and Archaea Genomes in Groups A, B, C, D, and X

    Table S4. Phylogenetic Distribution of Bacterial and Archaea Genomes in Groups A, B, C, D, and X

    Table S4. Phylogenetic distribution of bacterial and archaea genomes in groups A, B, C, D, and X. Group A a: Total number of genomes in the taxon b: Number of group A genomes in the taxon c: Percentage of group A genomes in the taxon a b c cellular organisms 5007 2974 59.4 |__ Bacteria 4769 2935 61.5 | |__ Proteobacteria 1854 1570 84.7 | | |__ Gammaproteobacteria 711 631 88.7 | | | |__ Enterobacterales 112 97 86.6 | | | | |__ Enterobacteriaceae 41 32 78.0 | | | | | |__ unclassified Enterobacteriaceae 13 7 53.8 | | | | |__ Erwiniaceae 30 28 93.3 | | | | | |__ Erwinia 10 10 100.0 | | | | | |__ Buchnera 8 8 100.0 | | | | | | |__ Buchnera aphidicola 8 8 100.0 | | | | | |__ Pantoea 8 8 100.0 | | | | |__ Yersiniaceae 14 14 100.0 | | | | | |__ Serratia 8 8 100.0 | | | | |__ Morganellaceae 13 10 76.9 | | | | |__ Pectobacteriaceae 8 8 100.0 | | | |__ Alteromonadales 94 94 100.0 | | | | |__ Alteromonadaceae 34 34 100.0 | | | | | |__ Marinobacter 12 12 100.0 | | | | |__ Shewanellaceae 17 17 100.0 | | | | | |__ Shewanella 17 17 100.0 | | | | |__ Pseudoalteromonadaceae 16 16 100.0 | | | | | |__ Pseudoalteromonas 15 15 100.0 | | | | |__ Idiomarinaceae 9 9 100.0 | | | | | |__ Idiomarina 9 9 100.0 | | | | |__ Colwelliaceae 6 6 100.0 | | | |__ Pseudomonadales 81 81 100.0 | | | | |__ Moraxellaceae 41 41 100.0 | | | | | |__ Acinetobacter 25 25 100.0 | | | | | |__ Psychrobacter 8 8 100.0 | | | | | |__ Moraxella 6 6 100.0 | | | | |__ Pseudomonadaceae 40 40 100.0 | | | | | |__ Pseudomonas 38 38 100.0 | | | |__ Oceanospirillales 73 72 98.6 | | | | |__ Oceanospirillaceae
  • Aliarcobacter Butzleri from Water Poultry: Insights Into Antimicrobial Resistance, Virulence and Heavy Metal Resistance

    Aliarcobacter Butzleri from Water Poultry: Insights Into Antimicrobial Resistance, Virulence and Heavy Metal Resistance

    G C A T T A C G G C A T genes Article Aliarcobacter butzleri from Water Poultry: Insights into Antimicrobial Resistance, Virulence and Heavy Metal Resistance Eva Müller, Mostafa Y. Abdel-Glil * , Helmut Hotzel, Ingrid Hänel and Herbert Tomaso Institute of Bacterial Infections and Zoonoses (IBIZ), Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, 07743 Jena, Germany; Eva.Mueller@fli.de (E.M.); Helmut.Hotzel@fli.de (H.H.); [email protected] (I.H.); Herbert.Tomaso@fli.de (H.T.) * Correspondence: Mostafa.AbdelGlil@fli.de Received: 28 July 2020; Accepted: 16 September 2020; Published: 21 September 2020 Abstract: Aliarcobacter butzleri is the most prevalent Aliarcobacter species and has been isolated from a wide variety of sources. This species is an emerging foodborne and zoonotic pathogen because the bacteria can be transmitted by contaminated food or water and can cause acute enteritis in humans. Currently, there is no database to identify antimicrobial/heavy metal resistance and virulence-associated genes specific for A. butzleri. The aim of this study was to investigate the antimicrobial susceptibility and resistance profile of two A. butzleri isolates from Muscovy ducks (Cairina moschata) reared on a water poultry farm in Thuringia, Germany, and to create a database to fill this capability gap. The taxonomic classification revealed that the isolates belong to the Aliarcobacter gen. nov. as A. butzleri comb. nov. The antibiotic susceptibility was determined using the gradient strip method. While one of the isolates was resistant to five antibiotics, the other isolate was resistant to only two antibiotics. The presence of antimicrobial/heavy metal resistance genes and virulence determinants was determined using two custom-made databases.
  • Swedres-Svarm 2019

    Swedres-Svarm 2019

    2019 SWEDRES|SVARM Sales of antibiotics and occurrence of antibiotic resistance in Sweden 2 SWEDRES |SVARM 2019 A report on Swedish Antibiotic Sales and Resistance in Human Medicine (Swedres) and Swedish Veterinary Antibiotic Resistance Monitoring (Svarm) Published by: Public Health Agency of Sweden and National Veterinary Institute Editors: Olov Aspevall and Vendela Wiener, Public Health Agency of Sweden Oskar Nilsson and Märit Pringle, National Veterinary Institute Addresses: The Public Health Agency of Sweden Solna. SE-171 82 Solna, Sweden Östersund. Box 505, SE-831 26 Östersund, Sweden Phone: +46 (0) 10 205 20 00 Fax: +46 (0) 8 32 83 30 E-mail: [email protected] www.folkhalsomyndigheten.se National Veterinary Institute SE-751 89 Uppsala, Sweden Phone: +46 (0) 18 67 40 00 Fax: +46 (0) 18 30 91 62 E-mail: [email protected] www.sva.se Text, tables and figures may be cited and reprinted only with reference to this report. Images, photographs and illustrations are protected by copyright. Suggested citation: Swedres-Svarm 2019. Sales of antibiotics and occurrence of resistance in Sweden. Solna/Uppsala ISSN1650-6332 ISSN 1650-6332 Article no. 19088 This title and previous Swedres and Svarm reports are available for downloading at www.folkhalsomyndigheten.se/ Scan the QR code to open Swedres-Svarm 2019 as a pdf in publicerat-material/ or at www.sva.se/swedres-svarm/ your mobile device, for reading and sharing. Use the camera in you’re mobile device or download a free Layout: Dsign Grafisk Form, Helen Eriksson AB QR code reader such as i-nigma in the App Store for Apple Print: Taberg Media Group, Taberg 2020 devices or in Google Play.
  • Do Routine Eye Exams Reduce Occurrence of Blindness from Type 2

    Do Routine Eye Exams Reduce Occurrence of Blindness from Type 2

    JFP_09.04_CI_finalREV 8/25/04 2:22 PM Page 732 Clinical Inquiries F ROM T HE F AMILY P RACTICE I NQUIRIES N ETWORK Do routine eye exams reduce photography. Median follow-up was 3.5 years occurrence of blindness (range, 1–8.5 years). from type 2 diabetes? The patients were divided into cohorts based on level of demonstrated retinopathy. The mean screening interval for a 95% probability of remaining free of sight-threatening retinopathy ■ EVIDENCE-BASED ANSWER was calculated for each grade of baseline Screening eye exams for patients with type 2 retinopathy. Screening patients with no retino- diabetes can detect retinopathy early enough so pathy every 5 years provided a 95% probability of treatment can prevent vision loss. Patients with- remaining free of sight-threatening retinopathy. out diabetic retinopathy who are systematically Patients with background retinopathy must be screened by mydriatic retinal photography have a screened annually to achieve the same result, and 95% probability of remaining free of sight-threat- patients with mild preproliferative retinopathy ening retinopathy over the next 5 years. If back- need to be screened every 4 months (Table). ground or preproliferative retinopathy is found at A systematic review2 of multiple small English- screening (Figure), the 95% probability interval language studies evaluating screening and moni- for remaining free of sight-threatening retino- toring of diabetic retinopathy found consistent pathy is reduced to 12 and 4 months, respective- results. Screening by direct or indirect ophthal- ly (strength of recommendation [SOR]: B, based moscopy alone detected 65% of patients with on 1 prospective cohort study).
  • Streptococcal Pharyngitis (Strep Throat)

    Streptococcal Pharyngitis (Strep Throat)

    Streptococcal Pharyngitis (Strep Throat) Maria Pitaro, MD ore throat is a very common reason for a visit to a health care provider. While the major treatable pathogen is group A beta hemolytic Streptococcus (GAS), Sthis organism is responsible for only 15-30% of sore throat cases in children and 5-10% of cases in adults. Other pathogens that cause sore throat are viruses (about 50%), other bacteria (including Group C beta hemolytic Streptococci and Neisseria gonorrhea), Chlamydia, and Mycoplasma. In this era of increasing microbiologic resistance to antibiotics, the public health goal of all clinicians should be to avoid the inappropriate use of antibiotics and to target treatment to patients most likely to have infection due to GAS. Clinical Manifestations and chest and in the folds of the skin and usually Pharyngitis due to GAS varies in severity. The spares the face, palms, and soles. Flushing of the Streptococcal Pharyngitis most common presentation is an acute illness with cheeks and pallor around the mouth is common, (Strep Throat). sore throat, fever (often >101°F/38.3°C), tonsillar and the tongue becomes swollen, red, and mottled Inflammation of the exudates (pus on the tonsils), and tender cervical (“strawberry tongue”). Both skin and tongue may oropharynx with adenopathy (swollen glands). Patients may also have peel during recovery. petechiae, or small headache, malaise, and anorexia. Additional physical Pharyngitis due to GAS is usually a self-limited red spots, on the soft palate. examination findings may include petechiae of the condition with symptoms resolving in 2-5 days even Photo courtesy soft palate and a red, swollen uvula.
  • International Journal of Systematic and Evolutionary Microbiology (2016), 66, 5575–5599 DOI 10.1099/Ijsem.0.001485

    International Journal of Systematic and Evolutionary Microbiology (2016), 66, 5575–5599 DOI 10.1099/Ijsem.0.001485

    International Journal of Systematic and Evolutionary Microbiology (2016), 66, 5575–5599 DOI 10.1099/ijsem.0.001485 Genome-based phylogeny and taxonomy of the ‘Enterobacteriales’: proposal for Enterobacterales ord. nov. divided into the families Enterobacteriaceae, Erwiniaceae fam. nov., Pectobacteriaceae fam. nov., Yersiniaceae fam. nov., Hafniaceae fam. nov., Morganellaceae fam. nov., and Budviciaceae fam. nov. Mobolaji Adeolu,† Seema Alnajar,† Sohail Naushad and Radhey S. Gupta Correspondence Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Radhey S. Gupta L8N 3Z5, Canada [email protected] Understanding of the phylogeny and interrelationships of the genera within the order ‘Enterobacteriales’ has proven difficult using the 16S rRNA gene and other single-gene or limited multi-gene approaches. In this work, we have completed comprehensive comparative genomic analyses of the members of the order ‘Enterobacteriales’ which includes phylogenetic reconstructions based on 1548 core proteins, 53 ribosomal proteins and four multilocus sequence analysis proteins, as well as examining the overall genome similarity amongst the members of this order. The results of these analyses all support the existence of seven distinct monophyletic groups of genera within the order ‘Enterobacteriales’. In parallel, our analyses of protein sequences from the ‘Enterobacteriales’ genomes have identified numerous molecular characteristics in the forms of conserved signature insertions/deletions, which are specifically shared by the members of the identified clades and independently support their monophyly and distinctness. Many of these groupings, either in part or in whole, have been recognized in previous evolutionary studies, but have not been consistently resolved as monophyletic entities in 16S rRNA gene trees. The work presented here represents the first comprehensive, genome- scale taxonomic analysis of the entirety of the order ‘Enterobacteriales’.
  • Sore Throat in Primary Care Project

    Sore Throat in Primary Care Project

    Family Practice, 2015, Vol. 32, No. 3, 263–268 doi:10.1093/fampra/cmv015 Advance Access publication 25 March 2015 Epidemiology Sore throat in primary care project: a clinical score to diagnose viral sore throat Selcuk Mistika,*, Selma Gokahmetoglub, Elcin Balcic, and Fahri A Onukd Downloaded from https://academic.oup.com/fampra/article-abstract/32/3/263/695324 by guest on 31 July 2019 aDepartment of Family Medicine, bDepartment of Microbiology, cDepartment of Public Health, Erciyes University Medical Faculty, Kayseri, Turkey, and dBunyamin Somyurek Family Medicine Centre, Kayseri, Turkey. *Correspondence to Prof. S. Mistik, Department of Family Medicine, Erciyes University Medical Faculty, Kayseri 38039, Turkey; E-mail: [email protected] Abstract Objective. Viral agents cause the majority of sore throats. However, there is not currently a score to diagnose viral sore throat. The aims of this study were (i) to find the rate of bacterial and viral causes, (ii) to show the seasonal variations and (iii) to form a new scoring system to diagnose viral sore throat. Methods. A throat culture for group A beta haemolytic streptococci (GABHS) and a nasopharyngeal swab to detect 16 respiratory viruses were obtained from each patient. Over a period of 52 weeks, a total of 624 throat cultures and polymerase chain reaction analyses were performed. Logistic regression analysis was performed to find the clinical score. Results. Viral infection was found in 277 patients (44.3%), and GABHS infection was found in 116 patients (18.5%). An infectious cause was found in 356 patients (57.1%). Rhinovirus was the most commonly detected infectious agent overall (highest in November, 34.5%), and the highest GABHS rate was in November (32.7%).
  • No Disclosures

    No Disclosures

    3/15/2017 Cases in Infectious Diseases NO DISCLOSURES Richard A. Jacobs, M.D., PhD. Case Records of the Massachusetts General Hospital Case Presentation A 22 yr old comes to the office complaining of the acute onset of unilateral weakness • Periventricular heterotopia due to an FLNA of the right side of his face. mutation and congenital alveolar dysplasia. Your diagnosis is Bell’s Palsy. N Engl J Med 2017; 376:562‐574 1 3/15/2017 What is Your Therapy? Etiology of Facial Nerve Palsy 100% • 50% are idiopathic (Bell’s Palsy) 1. Prednisolone • Herpes Simplex/Varicella Zoster (Geniculate 2. Acyclovir ganglion) – Direct invasion v. immunologic/inflammatory 3. Prednisolone + • Lyme disease (most common cause of bilateral FN acyclovir palsy) 4. Nothing • Other infections—CMV, EBV,HIV • Non‐infectious—Diabetes, sarcoid, tumors, 1 trauma Therapy of Bell’s Palsy Therapy of Bell’s Palsy • 839 patients enrolled within 72 hours of • Quite controversial onset of symptoms • Because of the association with herpes viruses – Placebo + placebo (206) the use of acyclovir has been felt to be – Prednisilone (60mg X 5 days then reduced beneficial by 10 mg/day) + placebo (210) • – Valacyclovir (1000mg TID X 7 Days) + Two well done prospective, randomized, placebo (207) controlled, blinded studies have been done – Valacyclovir X7 Days + prednisolone X10 Days (206) Lancet Neurol 2008;7:993‐1000 2 3/15/2017 Therapy of Bell’s Palsy Prednisilone Prednisilone • Case closed on therapy??? NO!! + valacyclovir Placebo • Other less powered studies and subgroup Valacyclovir analyses suggest that acyclovir might be + placebo beneficial in the most severe cases – Minimal or no movement of facial muscles and inability to close the eye Take Home Points Case Presentation • 57 yo male with polycystic kidney disease, • Early treatment (within 72 hours of gout, HTN and hyperlipidemia onset) recommended • Underwent bilateral nephrectomies and renal • For most cases prednisolone for 10 days transplant (CMV D +/R‐).
  • Clinical Microbiology 12Th Edition

    Clinical Microbiology 12Th Edition

    Volume 1 Manual of Clinical Microbiology 12th Edition Downloaded from www.asmscience.org by IP: 94.66.220.5 MCM12_FM.indd 1 On: Thu, 18 Apr 2019 08:17:55 2/12/19 6:48 PM Volume 1 Manual of Clinical Microbiology 12th Edition EDITORS-IN-CHIEF Karen C. Carroll Michael A. Pfaller Division of Medical Microbiology, Departments of Pathology and Epidemiology Department of Pathology, The Johns Hopkins (Emeritus), University of Iowa, University School of Medicine, Iowa City, and JMI Laboratories, Baltimore, Maryland North Liberty, Iowa VOLUME EDITORS Marie Louise Landry Robin Patel Laboratory Medicine and Internal Medicine, Infectious Diseases Research Laboratory, Yale University, New Haven, Connecticut Mayo Clinic, Rochester, Minnesota Alexander J. McAdam Sandra S. Richter Department of Laboratory Medicine, Boston Department of Laboratory Medicine, Children’s Hospital, Boston, Massachusetts Cleveland Clinic, Cleveland, Ohio David W. Warnock Atlanta, Georgia Washington, DC Downloaded from www.asmscience.org by IP: 94.66.220.5 MCM12_FM.indd 2 On: Thu, 18 Apr 2019 08:17:55 2/12/19 6:48 PM Volume 1 Manual of Clinical Microbiology 12th Edition EDITORS-IN-CHIEF Karen C. Carroll Michael A. Pfaller Division of Medical Microbiology, Departments of Pathology and Epidemiology Department of Pathology, The Johns Hopkins (Emeritus), University of Iowa, University School of Medicine, Iowa City, and JMI Laboratories, Baltimore, Maryland North Liberty, Iowa VOLUME EDITORS Marie Louise Landry Robin Patel Laboratory Medicine and Internal Medicine, Infectious Diseases Research Laboratory, Yale University, New Haven, Connecticut Mayo Clinic, Rochester, Minnesota Alexander J. McAdam Sandra S. Richter Department of Laboratory Medicine, Boston Department of Laboratory Medicine, Children’s Hospital, Boston, Massachusetts Cleveland Clinic, Cleveland, Ohio David W.